A 58-year-old man with a 3-year history of dilated cardiomyopathy (LVEF 28%) and symptomatic heart failure (NYHA Class III) is initiated on standard heart failure therapy. He is already on a beta-blocker and an ACE inhibitor. Which drug should be added next as the evidence-based third pillar of neurohormonal blockade?